Gaur, Tarang
Poddutoori, Ramulu
Khare, Leena
Bagal, Bhausaheb
Rashmi, Sonal
Patkar, Nikhil
Tembhare, Prashant
PG, Subramanian
Shetty, Dhanlaxmi
Dutt, Amit
Zhang, Qi
Konopleva, Marina
Platzbeckar, Uwe
Gupta, Sudeep
Samajdar, Susanta
Ramchandra, Murali
Khattry, Navin
Hasan, Syed K.
Funding for this research was provided by:
Tata Memorial Centre (TRAC/1019/900516/001)
Article History
Received: 5 May 2023
Accepted: 7 July 2023
First Online: 29 July 2023
Declarations
:
: <i>Institutional Ethics Committee:</i> All patients and donors in cluded in this study provided written informed consent following the Declaration of Helsinki, and the ethics Committee of Tata Memorial Centre, Mumbai (TMC-IEC III) DCGI registration number:IECIII: ECR/149/Inst/MH/2013 approved the study (approval reference number: 900516/2018).<i>Institute Animal Ethics Committtee</i>: All NOD/SCID mice experiments were conducted in accordance with guidelines approved by animal ethics committee of Tata Memorial Centre, Mumbai (study reference approval number IAEC/13/2018).
: All authors have read the manuscript and provided their consent for the submission.
: XL102 was developed by Aurigene Oncology Limited, Bangalore, India which had entered in license agreement with Exelixis CA, USA. The work described in this manuscript was performed in the academic Hasan Lab at the non-profit Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) at Tata Memorial Centre with financial support from Department of Atomic Energy Government of India. The authors declare no competing financial interests.